Schrodinger, Inc. Earnings Recaps
Q2 2026
Aug 7, 2026
Shares jumped 13.8% after Schrodinger reported better-than-expected ACV growth and strong commercial momentum, driven by broad-based demand and early adoption of new AI-enabled products.
Key takeaways
- ACV grew 27% year-over-year to $29.6 million in Q2, with non-contribution ACV up 23%, hitting the high end of guidance.
- Notable customer traction includes large pharma, biotech, and materials science sectors, underpinning broad demand.
- Launch of Bunsen, an AI co-scientist, started in early access last week, expected to drive significant platform usage growth via a throughput-based licensing model.
- Bristol Myers Squibb expanded its partnership, adopting Bunsen widely, exemplifying large-scale platform deployment.
- Contribution ACV totaled $7 million, including extended funding from the Gates Foundation supporting predictive toxicology and battery research initiatives.
Q1 2026
May 7, 2026
Shares were essentially unchanged, rising 0.6% post-earnings, reflecting a mixed reception to Schrodinger’s first quarter 2026 results and guidance with steady execution but no clear upside catalyst.
Key takeaways
- Annual Contract Value (ACV) grew 12% year-over-year to $28.4 million, driven by scale-up with top 20 pharma customers and new products.
- Total revenue reached $58.6 million, with software revenue at $35.6 million, including 34% from hosted licenses, up from 24% last year, reflecting an ongoing transition.
- Drug discovery revenue contributed $23 million, supported by collaborations and equity stakes such as the recent Lilly acquisition of Ajax Therapeutics.
- Management emphasized innovation, highlighting the upcoming Bunsen AI co-scientist launch to potentially transform molecular discovery workflows.
- Despite positive operational momentum, the market appears cautious amid macroeconomic uncertainty and no major beat or outlook raise, keeping the stock reaction muted.